IMV to Present Clinical Translational Data from DeCidE1 Study of DPX-Survivac at SITC 2019 Annual Meeting
06 November 2019 - 12:01AM
Business Wire
Robust survivin-specific T cell responses
observed in recurrent late-stage ovarian cancer in nearly all
evaluable subjects
Survivin-specific T cells remain active and
proliferative over time, leading to T cell infiltration and the
repopulation of up to 90% of the tumor microenvironment
IMV Inc. (Nasdaq:IMV)(TSX:IMV), a clinical stage
biopharmaceutical company pioneering a novel class of
immunotherapies, today announced that translational data, including
comprehensive immune profiling of clinical samples from subjects
treated with IMV’s lead compound, DPX-Survivac, will be presented
during the 34th Annual Meeting of the Society for Immunotherapy of
Cancer (SITC), being held on November 6 – 10, 2019 in National
Harbor, MD.
In connection with DeCidE1, IMV’s ongoing Phase 1b/2 study of
DPX-Survivac in advanced recurrent ovarian cancer, the Company
conducted immune-profiling of peripheral blood mononuclear cell
(PBMC) and tumor samples to evaluate the program’s underlying
mechanism of action. The data suggest that the treatment regimen
per the study protocol induced robust and sustained
survivin-specific T cell responses from nearly all evaluable
subjects and T cell infiltration into tumors without loss of
functionality. Specifically, a comparison of T cell receptor
β-chain repertoire analyses between pre- and on-treatment tumor
biopsies shows new clonotypes can represent up to 90% of the
intratumoral T cell population.
“We are very pleased to present these translational clinical
data in advanced recurrent ovarian cancer at this important
scientific venue. Taken together with earlier data, this
comprehensive analysis continues to validate our new T cell therapy
mechanism,” said Frederic Ors, President and Chief Executive
Officer at IMV. “We find these data highly encouraging, as they
highlight some of the key distinctive features of our promising new
treatment for patients with this hard-to-reach cancer, as well as
for patients with one of the numerous other tumor types that
express survivin. We look forward to demonstrating how this effect
translates into patient benefits with upcoming topline data from
this study.”
Poster Presentation Details:
Poster Title: Comprehensive immune profiling of clinical
samples from subjects with advanced recurrent epithelial ovarian
cancer treated with a novel T cell activating therapy,
DPX-Survivac
Presenter: Brennan S. Dirk, PhD – IMV Inc, Dartmouth,
Nova Scotia
Abstract Number: P586
Date and Time: Poster will be displayed all day on Nov.
9, 2019, 7:00 am - 8:30 pm EST
Location: Poster Hall (Prince George AB)
SITC has published the official abstracts on its meeting website
in advance of the SITC Annual Meeting. The poster will be available
under Events, Webcasts and Presentations in the investors section
of IMV’s website on the day of presentation.
About DPX-Survivac
DPX-Survivac is the lead candidate in IMV’s new class of
immunotherapies that program targeted T cells in vivo. It has
demonstrated the potential for targeted, persistent, and durable T
cell generation. IMV believes this mechanism of action (MOA) is key
to generating durable solid tumor regressions. DPX-Survivac
consists of survivin-based peptides formulated in IMV’s proprietary
DPX drug delivery platform. DPX-Survivac is designed to work by
eliciting a CD8+ T cell immune response against cancer cells
presenting survivin peptides on their surface.
Survivin, recognized by the National Cancer Institute (NCI) as a
promising tumor-associated antigen, is broadly over-expressed in
most cancer types, and plays an essential role in antagonizing cell
death, supporting tumor-associated angiogenesis and promoting
resistance to chemotherapies. IMV has identified over 20 cancer
indications in which survivin can be targeted by DPX-Survivac.
DPX-Survivac has received Fast Track designation from the U.S.
Food and Drug Administration (FDA) as maintenance therapy in
advanced ovarian cancer, as well as orphan drug designation status
from the U.S. FDA and the European Medicines Agency (EMA) in the
ovarian cancer indication.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated
to making immunotherapy more effective, more broadly applicable,
and more widely available to people facing cancer and other serious
diseases. IMV is pioneering a new class of immunotherapies based on
the Company’s proprietary drug delivery platform. This patented
technology leverages a novel mechanism of action that enables the
programming of immune cells in vivo, which are aimed at generating
powerful new synthetic therapeutic capabilities. IMV’s lead
candidate, DPX-Survivac, is a T cell-activating immunotherapy that
combines the utility of the platform with a target: survivin. IMV
is currently assessing DPX-Survivac as a monotherapy in advanced
ovarian cancer, as well as a combination therapy in multiple
clinical studies with Merck. Connect at www.imv-inc.com.
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. In the press release, such forward-looking
statements include, but are not limited to, statements regarding
the FDA potentially granting accelerated regulatory approval of
DPX-Survivac. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful design and completion of clinical trials
and the receipt and timely receipt of all regulatory approvals. IMV
Inc. assumes no responsibility to update forward-looking statements
in this press release except as required by law. These
forward-looking statements involve known and unknown risks and
uncertainties and those risks and uncertainties include, but are
not limited to, our ability to access capital, the successful and
timely completion of clinical trials, the receipt of all regulatory
approvals and other risks detailed from time to time in our ongoing
quarterly filings and annual information form Investors are
cautioned not to rely on these forward-looking statements and are
encouraged to read IMV’s continuous disclosure documents, including
its current annual information form, as well as its audited annual
consolidated financial statements which are available on SEDAR at
www.sedar.com and on EDGAR at www.sec.gov/edgar.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191105005656/en/
Investor Relations
Marc Jasmin, Senior Director, Investor Relations, IMV O:
(902) 492-1819 ext : 1042 M: (514) 617-9481 E:
mjasmin@imv-inc.com
Josh Rappaport, Director, Stern IR O: (212) 362-1200 E:
josh.rappaport@sternir.com
Media
Delphine Davan, Director, Communications, IMV M: (514)
698 1046 E: ddavan@imv-inc.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024